Abstract
The mixed azines 3a–h and 4 were obtained by treating 3-hydrazonoindolin-2-one (2) with the appropriate aldehyde or dialdehyde. Treatment of 3b or 3c with formaldehyde or glutaric dialdehyde and the appropriate amine afforded the azine Mannich bases 5–7. The condensation of isatin or its N-Mannich base 8 with 1-aminopiperidine, 4-aminomorpholine and 1,4-diaminopiperazine gave 10a–d, 12 and 13. The Mannich bases 14 and 15 were obtained from 10a and 10b. Treatment of 2 with succinic, phthalic and quinolinic anhydride and pyromellitic dianhydride afforded compounds 16, 17a, 17b and 18, respectively. The synthesis of isatin Schiff bases incorporating a benzoylpiperidine, benzoylmorpholine and 1,4-dibezoylpiperazine moiety and their N-Mannich bases was investigated.
1 Introduction
The chemistry of isatin (2,3-indolinedione) and its derivatives has been the subject of wide and increasing interest, due to their wide range of biological and pharmacological activities. The extensive literature dealing with the chemistry and pharmacological activities of isatin and related compounds has been reviewed [1–7]. In particular, much interest has centered around Schiff and N-Mannich bases of isatin, which possess a broad spectrum of action including antibacterial [8–14], anticonvulsant [15–17], anti-HIV [10, 18–21], antifungal [3–7, 10], cytotoxic and anticancer [3, 22–27] activities, and this has stimulated further research in this field. On the other hand, a number of azines and mixed azines are receiving attention owing to their promising antibacterial and antifungal [28–30], antimalarial [31], cytotoxic [32–34] and antioxidant [35] activity.
In view of this, the present work is largely concerned with attempts to extend the scope of the reaction of isatin and its N-Mannich bases with hydrazine and related compounds such as N-amino-heterocycles to include the synthesis of some new mixed azines and Schiff bases having a 2-indolinone moiety as a structural unit.
2 Results and discussion
In the present study, isatin (1) was treated with hydrazine to give the hydrazone 2 [36]. The reaction of 2 with the appropriate aromatic aldehyde afforded a series of mixed azines 3-(arylidenehydrazono)indolin-2-ones (3a–h) in good to excellent yields (Scheme 1).

Synthesis of 3-(arylidenehydrazono)indolin-2-ones (3a–h) and Mannich bases of 3b.
In addition, the reaction of hydrazone 2 with dialdehydes such as glyoxal leads to the formation of the bis-azine, which reacts further with glyoxal to give the N-hydroxyacetaldehyde derivative 4 as the end-product. The analytical and spectral data are consistent with the structures proposed for compounds 3a–h and 4. The mass spectra of 3a–h contain peaks of the respective molecular ions and showed very similar cleavage patterns. The base peak in the spectra of these compounds is due to the loss of C=O to give ions of type A (Scheme 2), except for compounds 3c and 3h, which showed intense peaks corresponding to the loss of C=O at m/z = 264 (86 %) and 271 (73 %), respectively. Cleavage at the azino group of compounds 3a–h leads to a peak at m/z = 145 due to the ion B. These spectral data are in line with the reported studies on the mass spectra of isatin and its derivatives [37–39].

Mass fragmentation pattern of 3a.
Although potentially interesting, the literature of Mannich bases related to azines is limited [33, 40]. The Mannich reaction of azines of the type 3 is of particular interest, because it provides access to mixed azines having a potential basic side chain of alkaloidal nature. This has been realized by treating 3-[(4-(dimethylamino)benzylidene)hydrazono]indolin-2-one (3b) with formaldehyde and piperidine, morpholine, tetrahydroisoquinoline and diethanolamine to give the corresponding N-Mannich bases 5a–d, respectively (Scheme 1).
The reaction of the mixed azine 3c with piperazine and formaldehyde proceeded equally well providing 1,1′-[piperazine-1,4-diylbis(methylene)]-bis[3-((4-methylbenzylidene)hydrazono)indolin-2-one] (6) (Scheme 3). It is interesting in this connection that treatment of 3c with glutaric dialdehyde and dimethylamine or piperidine led to the formation of the bis-(Mannich base) (7a) and the 1,1’-[1,5-di(piperidin-1-yl)] analogue 7b, respectively, via a double Mannich reaction.

Synthesis of bis-(Mannich bases) of the mixed azine 3c.
Although the utility of aromatic and heterocyclic amines in the synthesis of isatin Schiff bases was well established [1–6], the use of N-amino-heterocycles in such reactions was less widely recognized and had seen limited use [41]. The condensation of 1 or the Mannich base 8 with N-amino-heterocycles related to piperidine, morpholine and piperazine could be valuable in the synthesis of new isatin Schiff bases with an alkaloid partial structure, as depicted in Scheme 4.

Reaction of 1 or its Mannich base 8 with N-amino-heterocycles.
In view of that, 1 was treated with 1-aminopiperidine (9a) and 4-aminomorpholine (9b) to give 3-(piperidin-1-ylimino)indolin-2-one (10a) and the 3-(morpholinoimino) analogue 10b, respectively. A similar treatment of 1-(piperidinomethyl)isatin (8) [42] with 9a and 9b afforded the Schiff–Mannich bases 10c and 10d. Analogously, treating 1 and 8 with 1,4-diaminopiperazine (11) led to the formation of 12 and the bis-(Mannich base) 13, respectively. In addition, the Mannich reaction of 10a with formaldehyde and morpholine gave 1-(morpholinomethyl)-3-(piperidin-1-ylimino)indolin-2-one (14). A similar reaction takes place between 10b and piperazine yielding the bis-(Mannich base) 15. The formation of compounds 10–15 is of interest, because piperidine, morpholine and piperazine are significant classes of heterocycles and constituents of various important natural and synthetic bioactive compounds. In addition, Mannich bases incorporating a morpholine or piperazine moiety are known as antimicrobial agents [43–49].
On the other hand, the hydrazone 2 could conceivably function as a precursor to Schiff bases derived from N-amino-heterocycles. This has been achieved by the condensation of 2 with succinic anhydride to give 1-(2-oxoindolin-3-ylidenamino)pyrrolidine-2,5-dione (16). A similar reaction of 2 with phthalic anhydride and quinolinic anhydride led to the formation of compounds 17a and 17b, respectively. In addition, the pyrrolo[3,4-f]isoindole-1,3,5,7(2H,6H)-tetraone (18) was obtained from 2 and pyromellitic dianhydride (Scheme 5).

Condensation of the hydrazone 2 with acid anhydrides.
In the course of this study, the Schiff base 19 [50] has been used as a precursor for the synthesis of isatin Schiff bases incorporating a benzoylpiperidine, benzoylmorpholine and 1,4-dibenzoylpiperazine moiety. Thus, the Schiff bases 20a, 20b and 21 were obtained by treating 19 with the appropriate heterocyclic amine (Scheme 6).

Synthesis of Schiff and Mannich bases incorporating N-benzoyl-heterocycles.
Application of the Mannich reaction to the new Schiff bases 20a and 20b using piperidine and morpholine is of particular interest, because it offers access to compounds 22a and 22b, incorporating two piperidine or two morpholine moieties. The analogous reaction of 20a with piperazine afforded the 1,4-bis(3-imino-2-oxoindolinyl) substituted piperazine 23.
3 Experimental section
All melting points (uncorrected) were determined on a Gallenkamp electric melting point apparatus (Sanyo Gallenkamp, Southborough, UK). Elemental microanalyses were carried out on Carlo Erba 1108 Elemental Analyzer (Heraeus, Hanau, Germany) at the Microanalytical Unit, Faculty of Science, Cairo University. Infrared spectra were measured on a Mattson 5000 FTIR spectrometer (Mattson Instruments, Inc., Madison, WI, USA). 1H and 13C NMR data were obtained in [D6]DMSO solution on a Varian XL 300 MHz instrument (Varian, Inc., CA, USA) using TMS as the internal standard. Chemical shifts are reported in ppm (δ) downfield from internal TMS. Mass spectra were recorded on a GC-MS QP-1000 EX Shimadzu instrument (Shimadzu, Tokyo, Japan). The course of the reaction and the purity of the synthesized compounds were monitored by TLC using EM science silica gel coated plates, 0.25 nm, 60 GF 254 (Merck, Germany) with visualization by irradiation with an ultraviolet lamp. Compounds 4, 7a, 7b, 13, 17a, 17b, 18, 21 and 22a are of limited solubility in common 1H NMR solvents. Compounds 2 [14], 8 [20] and 19 [22] were prepared as previously described. All chemicals used were of pure grade and were purchased from Aldrich, WI, USA.
3.1 3-(Arylidenehydrazono)indolin-2-ones 3a–h
A mixture of 2 [14] (1.61 g, 10 mmol) and the appropriate aromatic aldehyde (10 mmol) in ethanol (80 mL) and acetic acid (0.5 mL) was refluxed for 4 h. After standing at room temperature (r.t.) for 24 h, the product obtained was filtered and crystallized from ethanol to give 3a–h.
3.1.1 3-(Benzylidenehydrazono)indolin-2-one (3a)
M.p. 198 °C. Yield 68 % (red crystals). – IR (KBr): v = 3412 (NH), 1729 (CO), 1613 (C=N), 1584, 1350, 1265, 750 cm–1. – MS (EI, 70 eV): m/z (%) = 249 (1) [M]+, 221 (100) [M–CO]+, 194 (13), 145 (5), 118 (55), 117 (15), 104 (20), 77 (87). – C15H11N3O (249.27): calcd. C 72.28, H 4.45, N 16.86; found C 72.20, H 4.41, N 16.79.
3.1.2 3-((4-(Dimethylamino)benzylidene)hydrazono)indolin-2-one (3b)
M.p. 218 °C. Yield 85 % (dark-red crystals). – IR (KBr): v = 3410 (NH), 1729 (CO), 1609 (C=N), 1521, 1431, 1327, 870 cm–1. – 1H NMR ([D6]DMSO): vδ = 3.09 (s, 6H, NMe2), 6.76–8.24 (m, 8H, aromatic), 8.60 (s, 1H, -N=CH-Ar), 10.73 ppm (s, 1H, NH). – 13C NMR ([D6]DMSO): δ = 40.05 (NMe), 110.46, 111.70, 117.09, 120.40, 122.05, 128.69, 131.17, 150.03, 153.03 (all Ar C), 132.49 (C-3 of 2-oxoindoline moiety), 144.34 (Ar-CH=N), 165.18 ppm (C=O). – MS (EI, 70 eV): m/z (%) = 292 (31) [M]+, 293 (80) [M+1]+, 263 (37), 264 (86) [M–CO]+, 145 (25), 147 (30), 120 (15), 118 (29), 117 (19), 104 (28), 91 (24). – C17H16N4O (292.34): calcd. C 69.85, H 5.52, N 19.17; found C 69.80, H 5.49, N 19.03.
3.1.3 3-((4-Methylbenzylidene)hydrazono)indolin- 2-one (3c)
M.p. 230 °C. Yield 75 % (red crystals). – IR (KBr): v = 3441 (NH), 1736 (CO), 1611 (C=N), 1457, 1327, 1201, 747 cm–1. – 1H NMR ([D6]DMSO): δ = 3.31 (s, 3H, Me), 6.89–7.95 (m, 8H, aromatic), 8.58 (s, 1H, -N=CH-Ar), 10.83 ppm (s, 1H, NH). – MS (EI, 70 eV): m/z (%) = 263 (2) [M]+, 262 (4) [M–1]+, 248 (2) [M–Me]+, 235 (100) [M–CO]+, 145 (4), 118 (53), 117 (16), 91 (57). – C16H13N3O (263.29): calcd. C 72.99, H 4.98, N 15.96; found C 72.91, H 4.92, N 15.89.
3.1.4 3-(2-(4-Methoxybenzylidene)hydrazono)indolin- 2-one (3d)
M.p. 188 °C. Yield 88 % (orange crystals). – IR (KBr): δ = 3449 (NH), 1719 (CO), 1605 (C=N), 1530, 1420, 1260, 1167, 740 cm–1. – 1H NMR ([D6]DMSO): δ = 3.90 (s, 3H, OMe), 6.93–8.23 (m, 8H, aromatic), 8.68 (s, 1H, -N=CH-Ar), 9.13 ppm (s, 1H, NH). – MS (EI, 70 eV): m/z (%) = 279 (2) [M]+, 280 (1) [M+1]+, 264 (6) [M–Me]+, 251 (100) [M–CO]+, 172 (2) [M–(p-anisyl)]+, 145 (13), 134 (32), 118 (59), 117 (33), 107 (28) [p-anisyl]+, 92 (68) [C6H4O]+. – C16H13N3O2 (279.29): calcd. C 68.81, H 4.69, N 15.05; found C 68.79, H 4.60, N 14.97.
3.1.5 3-((4-Hydroxybenzylidene)hydrazono)indolin- 2-one (3e)
M.p. 261 °C. Yield 60 % (red crystals). – IR (KBr): v = 3350–3196 (broad, NH and OH), 1723 (CO), 1612 (C=N), 1533, 1436, 1285, 1186, 790 cm–1. – MS (EI, 70 eV): m/z (%) = 265 (2) [M]+, 264 (3) [M–1]+, 237 (100) [M–CO]+, 145 (7), 120 (28), 118 (61), 117 (16), 93 (25) [C6H4O]+. – C15H11N3O2 (265.27): calcd. C 67.92, H 4.18, N 15.84; found C 67.89, H 4.10, N 15.78.
3.1.6 3-((4-Hydroxy-3-methoxybenzylidene)hydrazono)indolin-2-one (3f)
M.p. 223 °C. Yield 66 % (dark-red crystals). – IR (KBr): v = 3469 (OH), 3317 (NH), 1719 (CO), 1661, 1620, 1427, 1291, 1210, 680 cm–1. – 1H NMR ([D6]DMSO): δ = 3.83 (s, 3H, OMe), 6.88–8.08 (m, 7H, aromatic), 7.55 (s, 1H, OH), 8.56 (s, 1H, -N=CH-Ar), 10.79 ppm (s, 1H, NH). – MS (EI, 70 eV): m/z (%) = 295 (21) [M]+, 264 (34) [M–OMe]+, 237 (100) [M–CO]+, 236 (19) [M–(OMe+CO)]+, 207(100), 179 (62), 152 (9), 102 (10), 90 (11). – C16H13N3O3 (295.29): calcd. C 65.08, H 4.44, N 14.23; found C 64.99, H 4.40, N 14.19.
3.1.7 3-(2-((Benzo[d][1,3]dioxol-5-yl)methylene)hydrazono)indolin-2-one (3g)
M.p. 243 °C. Yield 76 % (orange crystals). – IR (KBr): v = 3449 (NH), 1725 (CO), 1614 (C=N), 1422, 1267, 1022, 742 cm–1. – 1H NMR ([D6]DMSO): δ = 6.16 (s, 2H, O-CH2-O), 6.88–7.55 (m, 7H, aromatic), 8.57 (s, 1H, -N=CH-Ar), 10.80 ppm (s, 1H, NH). – MS (EI, 70 eV): m/z (%) = 293 (1) [M]+, 265 (100) [M–CO]+, 238 (11), 146 (13), 121 (28), 118 (36), 117 (18), 102 (10), 91 (26), 90 (35). – C16H11N3O3 (293.28): calcd. C 65.53, H 3.78, N 14.33; found C 65.57, H 3.70, N 14.29.
3.1.8 3-(2-((Naphthalen-1-yl)methylene)hydrazono)indolin-2-one (3h)
M.p. 223 °C. Yield 66 % (dark-red crystals). – IR (KBr): v = 3406 (NH), 1728 (CO), 1612 (C=N), 1436, 1334, 1180, 792 cm–1. – MS (EI, 70 eV): m/z (%) = 299 (3) [M]+, 298 (11) [M–1]+, 271 (73) [M–CO]+, 168(23), 145 (20), 127 (100) [1-naphthyl ion]+, 118 (32), 117 (17), 90 (27), 77 (35). – C19H13N3O (299.33): calcd. C 76.24, H 4.38, N 14.04; found C 76.20, H 4.31, N 13.98.
3.2 2-Hydroxy-2-((Z)-2-oxo-3-((E)- ((E)-2-((Z)-(2-oxoindolin-3-ylidene)hydrazono)-ethylidene)hydrazono)indolin-1-yl)acetaldehyde (4)
This compound was obtained from 2 (1.61 g, 10 mmol) and glyoxal (40 %, 0.7 mL, 5 mmol), following the procedure described for the synthesis of 3a–h. The product was crystallized from ethanol to give 4. M.p. 264 °C. Yield 60 % (yellow crystals). – IR (KBr): v = 3413 (OH), 3329 (NH), 1682 (CO), 1620, 1597, 1554, 1462, 1370, 1173, 730 cm–1. – MS (EI, 70 eV): m/z (%) = 401 (11) [M–1]+, 400 (41) [M–2]+, 290 (20), 199 (21), 173 (44), 146 (43), 144 (16), 118 (100), 117 (34), 91 (42), 59 (10). – C20H14N6O4 (402.36): calcd. C 59.70, H 3.51, N 20.89; found C 59.68, H 3.49, N 20.83.
3.3 Synthesis of the N-Mannich bases 5a–d
A solution of 3b (0.87 g, 3 mmol), formalin (37 %, 0.28 mL, 3.5 mmol) and the appropriate sec-amine (3 mmol) in ethanol (40 mL) was heated on a steam bath for 45 min. After standing at r.t. for 48 h, the product obtained was filtered and crystallized from ethanol to give 5a–d.
3.3.1 3-(2-(4-(Dimethylamino)benzylidene)hydrazono)-1-(piperidin-1-ylmethyl)indolin-2-one (5a)
M.p. 193 °C. Yield 70 % (orange crystals). – IR (KBr): v = 1724 (CO), 1607 (C=N), 1557, 1411, 1316, 1206, 1173, 1036, 755 cm–1. – 1H NMR ([D6]DMSO): δ = 1.35–1.46 (m, 6H, 3-H2, 4-H2, 5-H2 of piperidine), 2.50 (m, 4H, 2-H2, 6-H2 of piperidine), 3.07 (s, 6H, NMe2), 4.45 (s, 2H, N-CH2-N of side chain), 6.84–8.29 (m, 8H, aromatic), 8.64 ppm (s, 1H, -N=CH-Ar). – MS (EI, 70 eV): m/z (%) = 294 (3) [M–(CH2NC5H10)]+, 292 (32), 264 (100), 263 (40), 145 (35), 131 (21), 118 (34), 117 (20), 104 (25), 98 (25) [CH2NC5H10]+, 84 (52) [NC5H10]+. – C23H27N5O (389.49): calcd. C 70.92, H 6.99, N 17.98; found C 70.89, H 6.90, N 17.91.
3.3.2 3-((4-(Dimethylamino)benzylidene)hydrazono)- 1-(morpholinomethyl)indolin-2-one (5b)
M.p. 224 °C. Yield 75 % (orange crystals). – IR (KBr): v = 1725 (CO), 1606 (C=N), 1547, 1410, 1311, 1206, 1166, 1027, 765 cm–1. – 1H NMR ([D6]DMSO): δ = 3.00 (m, 4H, CH2–N–CH2 of morpholine), 3.04 ( s, 6H, NMe2), 3.54 (m, 4H, CH2–O–CH2 of morpholine), 4.45 (s, 2H, N-CH2-N of side chain), 6.80–8.30 (m, 8H, aromatic), 8.63 ppm (s, 1H, -N=CH-Ar). – 13C NMR ([D6]DMSO): δ = 40.07 (NMe2), 51.54 (C-2, C-6 of morpholine), 61.30 (C-3, C-5 of morpholine), 66.12 (N-CH2-N of side chain), 116.42, 117.80, 120.33, 122.71, 128.39, 131.35, 131.70, 145.22, 153.17 (all Ar C), 132.49 (C-3 of 2-oxoindoline moiety), 149.01 (Ar-CH=N), 165.50 ppm (C=O). – MS (EI, 70 eV): m/z (%) = 391(4) [M]+, 392 (1) [M+1]+, 306 (4), 292 (4), 264 (9), 147 ((7), 145 (4), 120 (3), 118 (3), 100 (100) [morpholinomethyl ion]+, 91 (3), 56 (10). – C22H25N5O2 (391.47): calcd. C 67.50, H 6.44, N 17.89; found C 67.55, H 6.40, N 17.80.
3.3.3 3-(2-(4-(Dimethylamino)benzylidene)hydrazono)-1-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)indolin-2-one (5c)
M.p. 175 °C. Yield 45 % (orange crystals). – IR (KBr): v = 1712 (CO), 1610 (C=N), 1515, 1465, 1365, 1176, 1047, 746 cm–1. – 1H NMR ([D6]DMSO): δ = 2.69–2.97 (m, 4H, CH2–CH2), 3.09 (s, 6H, NMe2), 3.86 (s, 2H, CH2), 4.60 (s, 2H, N-CH2-N), 6.76–7.86 (m, 12H, aromatic), 8.72 ppm (s, 1H, -N=CH-Ar). – MS (EI, 70 eV): m/z (%) = 437 (4) [M]+, 305 (2), 291 (3), 264 (10), 158 (15), 147 (69), 146 (80), 145 (62), 144 (100), 132 (96), 117 (53), 118 (80), 77 (61). – C27H27N5O (437.54): calcd. C 74.12, H 6.22, N 16.01; found C 74.04, H 6.18, N 16.08.
3.3.4 3-(2-(4-(Dimethylamino)benzylidene)hydrazono)-1-((bis(2-hydroxyethyl)amino)-methyl)indolin- 2-one (5d)
M.p. 221 °C. Yield 61 % (dark-orange crystals). – IR (KBr): v = 3446 (OH), 1707 (CO), 1610 (C=N), 1513, 1465, 1367, 1174, 1045, 748 cm–1. – 1H NMR ([D6]DMSO): δ = 2.51 [t, 4H, N(CH2)2], 2.56 [s, 2H, 2 × OH], 3.03 (s, 6H, NMe2), 3.46 (t, 4H, 2 × CH2OH), 4.20 (s, 2H, N-CH2-N), 6.81–8.12 (m, 8H, aromatic), 8.64 ppm (s, 1H, -N=CH-Ar). – 13C NMR ([D6]DMSO): δ = 40.31 (NMe2), 53.89 (NCH2), 56.01 (CH2OH), 73.34 (N-CH2-N), 117.06, 120.40, 121.34, 122.09, 125.46, 127.02, 131.20, 132.25, 144.40, 153.09 (all Ar C), 138.06 (C-3 of 2-oxoindoline moiety), 150.03 (Ar-CH=N), 165.17 ppm (C=O). – MS (EI, 70 eV): m/z (%) = 409 (1) [M]+, 290 (12), 264 (37), 205 (2), 145 (100), 133 (26), 117 (87), 118 (31), 104 (21), 90 (77), 77 (28). – C22H27N5O3 (409.48): calcd. C 64.53, H 6.65, N 17.10; found C 64.66, H 6.60, N 17.15.
3.4 1,1’-[Piperazine-1,4-diylbis(methylene)]-bis[3-((4-methylbenzylidene)-hydrazono)-indolin-2-one] (6)
A solution of 3c (0.79 g, 3 mmol), formalin (37 %, 0.3 mL, 4 mmol) and piperazine (0.13 g, 1.5 mmol) in ethanol (40 mL) was refluxed for 2 h, and then left to stand overnight. The product obtained was filtered and crystallized from ethanol to give 6. M.p. 235 °C. Yield 72 % (orange crystals). – IR (KBr): v = 1726 (CO), 1629 (C=N), 1605, 1463, 1335, 1206, 1161, 754 cm–1. – 1H NMR (CDCl3): δ = 2.40 (s, 6H, 2 Me), 2.57 [br s, 8H, N(CH2CH2)2N], 4.47 (s, 4H, 2 CH2N), 7.09–7.99 (m, 16H, aromatic), 8.59 ppm [s, 2H, 2 × N=CH-Ar)]. – MS (EI, 70 eV): m/z (%) = 636 (6) [M]+, 637 (3) [M+1]+, 621 (6) [M–Me]+, 276 (3), 262 (5), 235 (100), 159 (5), 132 (9), 104 (13), 84 (14) [N(CH2CH2)2N]+. – C38H36N8O2 (636.74): calcd. C 71.68, H 5.70, N 17.60; found C 71.60, H 5.67, N 17.55.
3.5 1,1’-[1,5-Bis(dimethylamino)pentane-1,5-diyl]bis[3-((4-methylbenzylidene)-hydrazono)-indolin-2-one] (7a)
A mixture of 3c (0.79 g, 3 mmol), dimethylamine (40 %, 0.35 mL, 3 mmol) and glutaric dialdehyde (25 %, 0.6 mL, 1.5 mmol) in ethanol (20 mL) was heated on a steam bath for 1 h, and then left to stand overnight. The product obtained was filtered and crystallized from ethanol to give 7a. M.p. 210 °C. Yield 38 % (reddish-brown powder). – IR (KBr): v = 1679 (CO), 1614 (C=N), 1605, 1593, 1462, 1368, 1333, 1204, 1175, 748 cm–1. – MS (EI, 70 eV): m/z (%) = 680 (12) [M]+, 445 (13), 235 (100), 234 (27), 208 (22), 201 (13), 146 (22), 118 (59), 117 (20), 91(75), 68(15). – C41H44N8O2 (680.84): calcd. C 72.33, H 6.51, N 16.46; found C 72.25, H 6.48, N 16.40.
3.6 1,1’-[1,5-Di(piperidin-1-yl)pentane-1,5-diyl]bis[3-((4-methylbenzylidene)-hydrazono)-indolin-2-one] (7b)
This compound was synthesized from 3c (0.79 g, 3 mmol), piperidine (0.25 g, 3 mmol) and glutaric dialdehyde (25 %, 0.6 mL, 1.5 mmol), following the procedure described for the synthesis of 7a. The product was crystallized from ethanol to give 7b. M.p. 232 °C. Yield 50 % (yellowish-brown crystals). – IR (KBr): v = 1682 (CO), 1620 (C=N), 1550, 1461, 1340, 1187, 749 cm–1. – MS (EI, 70 eV): m/z (%) = 761 (0.6), 760 [M]+, 328 (23), 210 (10), 171 (34), 133 (28), 118 (21), 91 (31), 77 (30). – C47H52N8O2 (760.97): calcd. C 74.18, H 6.89, N 14.73; found C 74.10, H 6.81, N 14.78.
3.7 Synthesis of the Schiff bases 10a, b
A solution of 1 (0.88 g, 6 mmol) and 9a (0.6 g, 6 mmol) or 9b (0.61 g, 6 mmol) in ethanol (40 mL) and acetic acid (0.3 mL) was refluxed for 40 min. The precipitated product was filtered and washed with boiling ethanol (3 × 15 mL) to give 10a, b.
3.7.1 3-(Piperidin-1-ylimino)indolin-2-one (10a)
M.p. 235 °C. Yield 70 % (dark-yellow crystals). – IR (KBr): v = 3124 (NH), 1702 (CO), 1560, 1453, 1020, 694 cm–1. –1H NMR ([D6]DMSO): δ = 1.39–1.48 (m, 6H, 3-H2, 4-H2, 5-H2 of piperidine), 2.56 (m, 4H, 2-H2, 6-H2 of piperidine), 6.84–7.25 (m, 4H, aromatic), 10.18 ppm (s, 1H, NH). – MS (EI, 70 eV): m/z (%) = 229 (12) [M]+, 228 (14) [M–1]+, 147 (21), 145 (13) [M–(NC5H10)]+, 117 (17) [M–(NC5H10+CO)]+, 118 (19), 113 (15), 98 (21), 84 (51) [NC5H10]+, 69 (51), 60 (100). – C13H15N3O (229.28): calcd. C 68.10, H 6.59, N 18.33; found C 68.18, H 6.54, N 18.28.
3.7.2 3-(Morpholinoimino)indolin-2-one (10b)
M.p. 190 °C. Yield 72 % (yellow crystals). – IR (KBr): v = 3178 (NH), 1708 (CO), 1615, 1561, 1453, 1133, 749 cm–1. – 1H NMR ([D6]DMSO): δ = 3.77 (m, 4H, CH2–N–CH2 of morpholine), 3.89 (m, 4H, CH2–O–CH2 of morpholine), 6.77–7.42 (m, 4H, aromatic), 10.66 ppm (s, 1H, NH). – MS (EI, 70 eV): m/z (%) = 231 (11) [M]+, 232 (2) [M+1]+, 147 (30), 145 (7) [M–(morpholinyl ion)]+, 118 (86), 117 (24) [M–(morpholinyl ion+CO)]+, 90 (15), 86 (100) [morpholinyl ion]+, 85 (13). – C12H13N3O2 (231.25): calcd. C 62.33, H 5.67, N 18.71; found C 62.29, H 5.60, N 18.69.
3.8 Synthesis of the Schiff–Mannich bases 10c, d
These compounds were obtained from the Mannich base 8 [20] (0.49 g, 2 mmol) and 9a or 9b (2 mmol), in the manner described for the synthesis of 10a, b. The product was filtered and washed with boiling ethanol (3 × 15 mL) to give 10c, d.
3.8.1 3-(Piperidin-1-ylimino)-1-(piperidin-1-ylmethyl)indolin-2-one (10c)
M.p. >300 °C. Yield 30 % (pale-yellow powder). – IR (KBr): v = 1701 (CO), 1547, 1398, 1339, 1020, 685 cm–1. – 1H NMR ([D6]DMSO): δ = 1.33–1.49 [m, 12H, 2 × (3-H2, 4-H2, 5-H2 of piperidine)], 2.48 (m, 4H, 2-H2, 6-H2 of piperidine), 2.53 (m, 4H, 2-H2, 6-H2 of piperidine), 4.14 (s, 2H, N-CH2-N of side chain), 6.87–7.29 ppm (m, 4H, aromatic).– MS (EI, 70 eV): m/z (%) = 326 (20) [M]+, 327 (13) [M+1]+, 299 (14) [M+1(–CO)]+, 240 (14) [M–(NC5H10+2H)]+, 229 (13) [M–(CH2NC5H10+H)]+, 200 (14), 142 (19), 131 (15), 84 (14) [NC5H10]+. – C19H26N4O (231.25): calcd. C 69.91, H 8.03, N 17.16; found C 69.88, H 7.93, N 17.02.
3.8.2 3-(Morpholinoimino)-1-(piperidin-1-ylmethyl)indolin-2-one (10d)
M.p. 220 °C. Yield 40 % (yellow powder). – IR (KBr): v = 1708 (CO), 1609, 1565, 1398, 1319, 1028, 748 cm–1. – 1H NMR ([D6]DMSO): δ = 1.32–1.42 (m, 6H, 3-H2, 4-H2, 5-H2 of piperidine), 2.44 (m, 4H, 2-H2, 6-H2 of piperidine), 3.21 (m, 4H, CH2–N–CH2 of morpholine), 3.67 (m, 4H, CH2–O–CH2 of morpholine), 4.10 (s, 2H, N-CH2-N of side chain), 6.81–7.27 ppm (m, 4H, aromatic). – MS (EI, 70 eV): m/z (%) = 328 (10) [M]+, 329 (13) [M+1]+, 301 (7), 230 [M–CH2NC5H10]+, 147 (24), 145 (11), 130 (15), 118 (67), 98 (25) [CH2NC5H10]+, 86 (77) [morpholinyl ion]+, 84 (30) [NC5H10]+, 69 (66), 57 (89). – C18H24N4O2 (328.41): calcd. C 65.83, H 7.37, N 17.06; found C 65.79, H 7.30, N 16.94.
3.9 3,3’-(Piperazine-1,4-diylbis(azan- 1-yl-1-ylidene))diindolin-2-one (12)
This compound was obtained from 1 (0.37 g, 2.5 mmol) and 11 (0.15 g, 1.26 mmol), following the procedure described for the synthesis of 10a, b. The product was filtered and washed with boiling ethanol (3 × 15 mL) to give 12. M.p. 248 °C. Yield 38 % (pale-yellow powder). – IR (KBr): v = 3446 (NH), 1710 (CO), 1615 (C=N), 1576, 1460, 1340, 1177, 742 cm–1. – 1H NMR ([D6]DMSO): δ = 4.13 [br s, 8H, N(CH2CH2)2N], 6.79–751 (m, 8H, aromatic), 10.71 ppm (s, 1H, NH). – 13C NMR ([D6]DMSO): δ = 55.62 [N(CH2CH2)2N], 118.51, 121.11, 124.27, 127.60, 131.84, 147.27 (all Ar C), 139.37 (C=N), 164.67 ppm (C=O). – MS (EI, 70 eV): m/z (%) = 374 (29) [M]+, 375 (10) [M+1]+, 346 (7) [M–CO]+, 318 (7) [M–(2CO+H)]+, 320 (18), 229 (17), 228 (41), 145 (14), 147 (40), 117 (8), 83 (100). – C20H18N6O2 (374.40): calcd. C 64.16, H 4.85, N 22.45; found C 64.05, H 4.80, N 22.39.
3.10 3,3’-(Piperazine-1,4-diylbis(azan- 1-yl-1-ylidene))bis(1-(piperidin- 1-ylmethyl)indolin-2-one) (13)
This compound was synthesized from 8 [20] (0.49 g, 2 mmol) and 11 (0.12 g, 1 mmol) by a procedure analogous to that for obtaining 12. The product was filtered and washed with boiling ethanol (3 × 15 mL) to give 13. M.p. 245 °C. Yield 60 % (yellow powder). – IR (KBr): v = 1719 (CO), 1610 (CN), 1559, 1446, 1056, 844 cm–1. – MS (EI, 70 eV): m/z (%) = 568 (34) [M]+, 569 (28) [M+1]+, 567 (29) [M–1]+, 539 (20) [M–(CO+H)]+, 512 (33) [M–(2CO+H)]+, 469 (25) [M–(CH2NC5H10+H)]+, 373 (29), 402 (32), 363 (31), 264 (31), 174 (37), 139 (36), 148 (17), 95 (44). – C32H40N8O2 (568.71): calcd. C 67.58, H 7.09, N 19.70; found C 67.50, H 7.11, N 19.68.
3.11 1-(Morpholinomethyl)-3-(piperidin- 1-ylimino)indolin-2-one (14)
A solution of 10a (0.68 g, 3 mmol) and formalin (37 %, 0.28 mL, 3.5 mmol) in ethanol (40 mL) was heated on a steam bath for 15 min, then morpholine (0.26 g, 3 mmol) was added, and the reaction mixture was refluxed for 1 h. After standing at r.t. for 48 h, the product obtained was filtered and crystallized from ethanol to give 14. M.p. 298 °C. Yield 32 % (orange crystals). – IR (KBr): v = 1721 (CO), 1630, 1581, 1406, 1338, 1023, 678 cm–1. – MS (EI, 70 eV): m/z (%) = 328 (21) [M]+, 329 (16) [M+1]+, 229 (15) [M–(morpholinomethyl ion)+H]+, 216 (20) [M–(CO+NC5H10)]+, 200 (15) [M–(CO+morpholinomethyl ion)]+, 101 (16), 87 (22), 84 (31). – C18H24N4O2 (328.41): calcd. C 65.83, H 7.37, N 17.06; found C 65.85, H 7.33, N 17.11.
3.12 1,1’-(Piperazine-1,4-diylbis(methylene))bis(3-(morpholinoimino)indolin-2-one) (15)
This compound was obtained from 10b (0.69 g, 3 mmol), formalin (37 %, 0.28 mL, 3.5 mmol) and piperazine (0.13 g, 1.5 mmol), following the procedure described for the synthesis of 14. After standing at r.t. for 72 h, the product obtained was filtered and crystallized from ethanol to give 15. M.p. 220 °C. Yield 35 % (orange crystals). – IR (KBr): v = 1675 (CO), 1607 (C=N), 1535, 1417, 1344, 1173, 741 cm–1. – 1H NMR ([D6]DMSO): δ = 2.33 [br s, 8H, N(CH2CH2)2N], 3.23 (m, 4H, CH2–N–CH2 of morpholine), 3.89 (m, 4H, CH2–O–CH2 of morpholine), 4.45 (s, 4H, 2 CH2N), 6.77–7.42 ppm (m, 8H, aromatic). – MS (EI, 70 eV): m/z (%) = 572 (55) [M]+, 573 (51) [M+1]+, 530 (62), 498 (77), 455 (65), 416 (60), 402 (57), 305 (63), 262 (73), 205 (69), 145 (41), 106 (84), 78 (100). – C30H36N8O4 (572.66): calcd. C 62.92, H 6.34, N 19.57; found C 62.89, H 6.30, N 19.49.
3.13 1-(2-Oxoindolin-3-ylideneamino)pyrrolidine-2,5-dione (16)
A mixture of 2 (0.6 g, 6 mmol) and succinic anhydride (0.96 g, 6 mmol) in acetic acid (20 mL) containing fused sodium acetate (0.2 g) was heated under reflux for 4 h. The reaction mixture was diluted with water (25 mL) and basified with ammonia. The product was filtered and crystallized from ethyl acetate to give 16. M.p. 240 °C. Yield 62 % (pale-brown powder). – IR (KBr): v = 3221 (NH), 2935 (CH aliphatic), 1712 (C=O of succinimide), 1678 (C=O), 1620 (C=N), 1154, 698 cm–1. – 1H NMR ([D6]DMSO): δ = 2.60 (s, 4H, 2 × CH2 of succinimide), 6.92–7.55 (m, 4H, aromatic), 11.22 ppm (s, 1H, NH). – MS (EI, 70 eV): m/z (%) = 243 (7) [M]+, 244 (2) [M+1]+, 215 (2) [M–CO]+, 161 (20), 145 (7) [M–pyrrolidinedione ion)]+, 132 (20), 117 (7), 98 (22) [pyrrolidinedione ion]+, 63 (100), 77 (21). – C12H9N3O3 (243.22): calcd. C 59.26, H 3.73, N 17.28; found C 59.20, H 3.69, N 17.20.
3.14 Synthesis of compounds 17a, b and 18
These compounds were obtained from 2 (0.6 g, 6 mmol) and phthalic anhydride (0.88 g, 6 mmol), or quinolinic anhydride (0.89 g, 6 mmol), or pyromellitic dianhydride (0.65 g, 3 mmol), following the procedure described for the synthesis of 16. The product was filtered and crystallized from ethanol to give 17a, b and from ethyl acetate to give 18.
3.14.1 2-(2-Oxoindolin-3-ylideneamino)isoindoline- 1,3-dione (17a)
M.p. 282 °C. Yield 60 % (dark-red powder). – IR (KBr): v = 3258 (NH), 1724 (CO), 1649 (CO), 1615, 1416, 1336, 1203, 1150, 751 cm–1. – MS (EI, 70 eV): m/z (%) = 291 (8) [M]+, 292 (1) [M+1]+, 290 (40) [M–1]+, 263 (2) [M–CO]+, 234 (44) [M–(2CO+2H)]+, 146 (2), 145 (34) [M–(phthalimido ion)]+, 117 (73), 118 (100), 76 (23). – C16H9N3O3 (291.26): calcd. C 65.98, H 3.11, N 14.43; found C 65.90, H 3.04, N 14.39.
3.14.2 6-(2-Oxoindolin-3-ylideneamino)- 6H-pyrrolo[3,4-b]pyridine-5,7-dione (17b)
M.p. >300 °C. Yield 55 % (dark-red powder). – IR (KBr): v = 3175 (NH), 1722 (CO), 1705 (CO), 1609 (C=N), 1570, 1466, 1342, 1203, 1109, 741 cm–1. – MS (EI, 70 eV): m/z (%) = 292 (10) [M]+, 293 (2) [M+1]+, 264 (3) [M–CO]+, 236 (10) [M–(2CO+H)]+, 161 (38), 123 (59), 117 (11), 118 (8), 77 (100). – C15H8N4O3 (292.25): calcd. C 61.65, H 2.76, N 19.17; found C 61.68, H 2.70, N 19.10.
3.14.3 2,6-Bis(2-oxoindolin-3-ylideneamino)pyrrolo[3,4-f]isoindole-1,3,5,7(2H,6H)-tetraone (18)
M.p. > 300 °C. Yield 40 % (dark-red powder). – IR (KBr): v = 3202 (NH), 1725 (CO), 1615, 1548, 1462, 1337, 1210, 1020, 750 cm–1. – MS (EI, 70 eV): m/z (%) = 506 (53) [M+2]+, 502 (51) [M–2]+, 465 (55), 298 (60), 264 (51), 213 (35), 144 (10), 143 (28), 117 (5), 84 (73), 83 (100). – C26H12N6O6 (504.41): calcd. C 61.91, H 2.40, N 16.66; found C 61.89, H 2.43, N 16.60.
3.15 Synthesis of the Schiff bases 20a, b and 21
A mixture of 19 [22] (0.88 g, 3 mmol) and piperidine (0.25 g, 3 mmol), or morpholine (0.26 g, 3 mmol), or piperazine (0.13 g, 1.5 mmol), in toluene (20 mL) was heated under reflux for 1 h. The product obtained on cooling was filtered and crystallized from ethanol to give compounds 20a, b and washed with boiling ethanol (3 × 15 mL) to give 21.
3.15.1 3-(4-(Piperidine-1-carbonyl)phenylimino)indolin-2-one (20a)
M.p. 198 °C. Yield 50 % (yellowish-green crystals). – IR (KBr): v = 3280 (NH), 1721 (CO), 1683 (CO), 1618, 1439, 1303, 1124, 1013, 783 cm–1. – 1H NMR ([D6]DMSO): δ = 1.27–1.31 (m, 6H, 3-H2, 4-H2, 5-H2 of piperidine), 4.10 (m, 4H, 2-H2, 6-H2 of piperidine), 6.71–8.07 (m, 8H, aromatic), 11.01 ppm (s, 1H, NH). – C20H19N3O2 (333.38): calcd. C 72.05, H 5.74, N 12.60; found C 72.11, H 5.70, N 12.58.
3.15.2 3-(4-(Morpholine-4-carbonyl)phenylimino)indolin-2-one (20b)
M.p. 200 °C. Yield 55 % (pale-brown powder). – IR (KBr): v = 3188 (NH), 1714 (CO), 1612, 1465, 1329, 1273, 1111, 1022, 879, 745 cm–1. – C19H17N3O3 (335.36): calcd. C 68.05, H 5.11, N 12.53; found C 68.12, H 5.00, N 12.49.
3.15.3 3-(4-(1-(4-(2-Oxoindolin-3-ylideneamino)benzoyl)piperazine-4-carbonyl)-phenylimino)indolin- 2-one (21)
M.p. 260 °C. Yield 47 % (pale-brown powder). – IR (KBr): v = 3214 (NH), 1714 (CO), 1608, 1512, 1466, 1330, 1199, 1016, 751 cm–1. – MS (EI, 70 eV): m/z (%) = 582 (18) [M]+, 583(16) [M+1]+, 581 (10) [M–1]+, 437 (18), 246 (21), 221 (12), 146 (100), 118 (9), 86 (36). – C34H26N6O4 (582.61): calcd. C 70.09, H 5.50, N 14.42; found C 70.11, H 5.49, N 14.38.
3.16 Synthesis of the Schiff–Mannich bases 22a, b
A solution of 20a (1 g, 3 mmol), or 20b (1 g, 3 mmol), formalin (37 %, 0.28 mL, 3.5 mmol) and piperidine or morpholine (3 mmol) in ethanol (40 mL) was heated on a steam bath for 45 min. After standing at r.t. for 24 h, the product obtained was filtered and crystallized from ethanol to give 22a, b.
3.16.1 1-(Piperidin-1-ylmethyl)-3-(4-(piperidine- 1-carbonyl)phenylimino)indolin-2-one (22a)
M.p. 180 °C. Yield 46 % (pale-brown powder). – IR (KBr): v = 1722 (CO), 1611 (C=N), 1469, 1382, 1273, 1112, 1020, 743 cm–1. – MS (EI, 70 eV): m/z (%) = 431 (5) [M+1]+, 277 (5), 232 (5), 187 (2), 165 (28), 120 (100), 117 (2), 112 (2), 84 (4). – C26H30N4O2 (430.54): calcd. C 72.53, H 7.02, N 13.01; found C 72.50, H 7.10, N 12.88.
3.16.2 3-(4-(Morpholine-4-carbonyl)phenylimino)- 1-(morpholinomethyl)indolin-2-one (22b)
M.p. 191 °C. Yield 51 % (pale-brown powder). – IR (KBr): v = 1715 (CO), 1619 (C=N), 1467, 1327, 1273, 1208, 1111, 1023, 747 cm–1. – 1H NMR ([D6]DMSO): δ = 2.54 [m, 8H, 2 × (CH2–N–CH2) of morpholine], 3.45 [m, 8H, 2 × (CH2–O–CH2) of morpholine], 4.33 (s, 2H, N-CH2-N), 6.77–7.28 ppm (m, 8H, aromatic). – MS (EI, 70 eV): m/z (%) = 434 (11) [M]+, 433 (2) [M–1]+, 406 (8), 348 (7), 334 (2), 158 (3), 133 (100), 105 (50), 77 (21). – C24H26N4O4 (434.49): calcd. C 66.34, H 6.03, N 12.89; found C 66.30, H 6.08, N 12.81.
3.17 1,4-Bis(((3-(piperidine-1-carbonyl)phenylimino)2-oxoindolin-1-yl)methyl)piperazine (23)
This compound was obtained from 20a (1 g, 3 mmol), formalin (37 %, 0.28 mL, 3.5 mmol) and piperazine (0.13 g, 1.5 mmol), following the procedure described for the synthesis of 22a, b. The product obtained was filtered and washed with boiling ethanol (3 × 15 mL) to give 23. M.p. 218 °C. Yield 46 % (orange powder). – IR (KBr): v = 1730 (CO), 1651 (CO), 1611 (C=N), 1469, 1352, 1273, 1196, 1045, 758 cm–1. – 1H NMR ([D6]DMSO): δ = 1.23–1.46 [m, 12H, 2 × (3-H2, 4-H2, 5-H2) of piperidine), 2.45 [m, 8H, 2 × (2-H2, 6-H2) of piperidine], 2.57 [br s, 8H, N(CH2CH2)2N], 4.34 (s, 4H, N-CH2-N), 7.06–7.65 ppm (m, 16H, aromatic). – MS (EI, 70 eV): m/z (%) = 776 (5) [M]+, 692 (4), 332 (5), 188 (2), 113 (9), 111 (19), 97 (42), 84 (8) 82 (37), 57 (100). – C46H48N8O4 (776.92): calcd. C 71.11, H 6.23, N 14.42; found C 71.01, H 6.26, N 14.39.
References
[1] J. F. Da Silva, S. J. Garden, A. C. Pinto, J. Braz. Chem. Soc. 2001, 12, 273.10.1590/S0103-50532001000300002Search in Google Scholar
[2] S. N. Pandeya, S. Smitha, M. Jyoti, S. K. Sridhar, Acta Pharm. 2005, 55, 27.Search in Google Scholar
[3] K. L. Vine, L. Matesic, J. M. Loke, M. Ranson, D. Skropeta, AnticancerAgents Med. Chem. 2009, 9, 397.10.2174/1871520610909040397Search in Google Scholar
[4] T. Aboul-Fadl, F. A. Bin-Jubair, Int. J. Res. Pharm. Sci. 2010, 1, 113.Search in Google Scholar
[5] B. Bhrigu, D. Pathak, N. Siddiqui, M. S. Alam, W. Ahsan, Int. J. Pharm. Sci. Drug Res.2010, 2, 229.Search in Google Scholar
[6] P. Pakravan, S. Kashanian, M. M. Khodaei, F. J. Harding, Pharmacol. Rep.2013, 65, 313.10.1016/S1734-1140(13)71007-7Search in Google Scholar
[7] G. Mathur, S. Nain, Med. Chem. 2014, 4, 417.10.1002/ejic.201490012Search in Google Scholar
[8] U. K. Singh, S. N. Pandeya, A. Singh, B. K. Srivastava, M. Pandey, Int. J. Pharm. Sci. Drug Res. 2010, 2, 151.Search in Google Scholar
[9] G. Cerchiaro, A. C. Ferreira, J. Braz. Chem. Soc.2006, 17, 1473.10.1590/S0103-50532006000800003Search in Google Scholar
[10] S. N. Pandeya, D. Sriram, G. Nath, E. De Clercq, Arzneim. Forsch.2000, 50, 55.10.1055/s-0031-1300164Search in Google Scholar
[11] S. K. Sridhar, M. Saravanan, A. Ramesh, Eur. J. Med. Chem.2001, 36, 615.10.1016/S0223-5234(01)01255-7Search in Google Scholar
[12] V. Ravichandran, S. Mohan, K. Suresh Kumar, Arkivoc2007, xiv, 51.10.3998/ark.5550190.0008.e07Search in Google Scholar
[13] S. S. Chhajed, M. S. Padwal, Int. J. Chem. Tech. Res. 2010, 2, 209.10.1002/nadc.19540022102Search in Google Scholar
[14] A. Jarrahpour, D. Khalili, E. De Clercq, C. Salmi, J. C. Brunel, Molecules2007, 12, 1720.10.3390/12081720Search in Google Scholar
[15] S. K. Sridhar, S. N. Pandeya, J. P. Stables, A. Ramesh, Eur. J. Pharm. Sci.2002, 16, 129.10.1016/S0928-0987(02)00077-5Search in Google Scholar
[16] M. Varma, S. N. Pandeya, K. N. Singh, J. P. Stables, Acta. Pharm.2004, 54, 49.Search in Google Scholar
[17] A. Gursoy, N. Karali, S. Buyuktimkin, S. Demirayak, A. C. Ekinci, H. Ozer, Farmaco1996, 51, 437.Search in Google Scholar
[18] S. K. Sridhar, S. N. Pandeya, E. De Clercq, Boll. Chim. Farm.2001, 140, 302.Search in Google Scholar
[19] S. N. Pandeya, D. Sriram, G. Nath, E. De Clercq, Eur. J. Med. Chem.2000, 35, 249.10.1016/S0223-5234(00)00125-2Search in Google Scholar
[20] S. N. Pandeya, D. Sriram, G. Nath, E. De Clercq, Pharm.Acta Helv. 1999, 74, 11.10.1016/S0031-6865(99)00010-2Search in Google Scholar
[21] T. R. Ball, B. Anand, P. Yogeeswari, D. Sriram, Bioorg. Med. Chem. Lett.2005, 15, 4451.10.1016/j.bmcl.2005.07.046Search in Google Scholar
[22] N. Karali, Eur. J. Med. Chem. 2002, 37, 909.10.1016/S0223-5234(02)01416-2Search in Google Scholar
[23] N. Karali, N. Terzioglu, A. Gursoy, Arch. Pharm. (Weinheim)2002, 335, 374.10.1002/1521-4184(200211)335:8<374::AID-ARDP374>3.0.CO;2-KSearch in Google Scholar
[24] V. R. Solomon, C. Hu, H. Lee, Bioorg. Med. Chem. 2009, 17, 7585.10.1016/j.bmc.2009.08.068Search in Google Scholar
[25] N. R. Penthala, T. R. Yerramreddy, N. R. Madadi, P. A. Crooks, Bioorg. Med. Chem. Lett. 2010, 20, 4468.Search in Google Scholar
[26] A. T. Taher, N. A. Khalil, E. M. Ahmed, Arch. Pharm. Res. 2011, 34, 1615.10.1007/s12272-011-1005-3Search in Google Scholar
[27] V. I. Chandran, L. Matesic, J. M. Locke, D. Skropeta, M. Ranson, K. L. Vine, Cancer Lett.2012, 316, 151.10.1016/j.canlet.2011.10.021Search in Google Scholar
[28] V. B. Kurteva, S. P. Simeonov, M. Stoilova-Disheva, Pharmacol. Pharm.2011, 2, 1.10.4236/pp.2011.21001Search in Google Scholar
[29] M. Revanasiddappa, T. Suresh, S. Khasim, S. C. Raghavendray, C. Basavaraja, S. D. Angadi, E-J. Chem.2008, 5, 395.10.1155/2008/328961Search in Google Scholar
[30] G. Gürkök, N. Altanlar, S. Suzen, Chemotherapy2009, 55, 15.10.1159/000166999Search in Google Scholar
[31] J. L. Vennerstrom, M. T. Makler, C. K. Angerhofer, J. A. Williams, Antimicrob. Agents Chemother.1995, 39, 2671.10.1128/AAC.39.12.2671Search in Google Scholar
[32] A. I. Khodair, P. Bertrand, Tetrahedron1998, 54, 4859.10.1016/S0040-4020(98)00170-7Search in Google Scholar
[33] H. I. Gul, M. Gul, J. Vepsälainen, E. Erciyas, O. Hänninen, Biol. Pharm. Bull.2003, 26, 631.10.1248/bpb.26.631Search in Google Scholar
[34] N. Haider, T. Kabicher, J. Käferböck, A. Plenk, Molecules2007, 12, 1900.10.3390/12081900Search in Google Scholar
[35] G. Gürkök, T. Coban, S. Suzen, J. Enzyme Inhib. Med. Chem.2009, 24, 506.10.1080/14756360802218516Search in Google Scholar
[36] B. Srinivas, V. Rajini Priya, G. Sridhar Babu, J. Venkateshwar Rao, P. S. Malathy, K. Raja Manohar, B. Chandara Prakash, L. Srikanth, Der Pharma Chemica2010, 2, 378.Search in Google Scholar
[37] R. J. Barbuch, N. P. Peet, J. E. Coutant, Org. Mass Spectr.1986, 21, 521.10.1002/oms.1210210814Search in Google Scholar
[38] R. S. Varma, A. P. Singh, S. P. Singh, Org. Mass Spectr.1992, 27, 17.10.1002/oms.1210270105Search in Google Scholar
[39] N. P. Peet, R. J. Barbuch, Org. Mass Spectr.1984, 19, 171.10.1002/oms.1210190405Search in Google Scholar
[40] H. I. Gul, H. Suleyman, M. Gul, Pharm. Biol. 2009, 47, 968.10.1080/13880200902967961Search in Google Scholar
[41] O. Bekircan, H. Bektas, Molecules2008, 13, 2126.Search in Google Scholar
[42] H. Hellmann, I. Löschmann, Chem. Ber. 1954, 87, 1684.10.1002/cber.19540871112Search in Google Scholar
[43] M. Ashok, B. S. Holla, B. Poojary, Eur. J. Med. Chem.2007, 42, 1095.10.1016/j.ejmech.2007.01.015Search in Google Scholar
[44] V. A. Pal’chikov, Russ. J. Org. Chem. 2013, 49, 787.10.1134/S1070428013060018Search in Google Scholar
[45] H. Bayrak, A. Demirbas, S. A. Karaoglu, N. Demirbas, Eur. J. Med. Chem.2009, 44, 1057.10.1016/j.ejmech.2008.06.019Search in Google Scholar
[46] H. Bayrak, A. Demirbas, N. Demirbas, S. A. Karaoglu, Eur. J. Med. Chem.2009, 44, 4362.10.1016/j.ejmech.2009.05.022Search in Google Scholar
[47] E. Wyrzykiewicz, M. Wendzonka, B. Kedzia, Eur. J. Med. Chem. 2006, 41, 519.10.1016/j.ejmech.2005.11.010Search in Google Scholar
[48] A. R. Foroumadi, S. Ghodsi, S. Emami, S. Najjari, N. Samadi, M. A. Faramarzi, L. Beikmohammadi, F. H. Shirazi, A. Shafiee, Bioorg. Med. Chem. Lett. 2006, 16, 3499.10.1016/j.bmcl.2006.03.103Search in Google Scholar
[49] Y. Cui, Y. Dang, Y. Yang, S. Zhang, R. Ji, Bioorg. Med. Chem. Lett. 2005, 15, 209.Search in Google Scholar
[50] T. I. El-Emary, Polish J. Chem. 1996, 70, 1143.Search in Google Scholar
©2015 by De Gruyter
Articles in the same Issue
- Frontmatter
- In this Issue
- About alkali metal dicyanamides: syntheses, single-crystal structure determination, DSC/TG and vibrational spectra of KCs[N(CN)2]2 and NaRb2[N(CN)2]3 · H2O
- Synthesis and crystal structure of the two-dimensional coordination compound potassium oxo-bis(hydroxylamido)-pyridine-2, 3-dicarboxylato-vanadate(V)
- Anti-inflammatory effect and isolation of phenylethanoid and acylated flavone glycosides from Panzeria alaschanica
- Synthesis and some reactions of functionalized 11,12-dihydro-5H-dibenzo[b,g]azonines
- Synthesis of some new mixed azines, Schiff and Mannich bases of pharmaceutical interest related to isatin
- Taraxastane-type triterpene saponins isolated from Pittosporum angustifolium Lodd.
- Synthesis and UV/Vis analysis of amino acid-derived bisurea-type receptors involving anion complexation
- Organoboranes and tetraorganoborates studied by 11B and 13C NMR spectroscopy and DFT calculations
- The stannides RE3Au6Sn5 (RE = La, Ce, Pr, Nd, Sm) – synthesis, structure, magnetic properties and 119Sn Mössbauer spectroscopy
- Synthesis and characterization of PbBaGeO4
Articles in the same Issue
- Frontmatter
- In this Issue
- About alkali metal dicyanamides: syntheses, single-crystal structure determination, DSC/TG and vibrational spectra of KCs[N(CN)2]2 and NaRb2[N(CN)2]3 · H2O
- Synthesis and crystal structure of the two-dimensional coordination compound potassium oxo-bis(hydroxylamido)-pyridine-2, 3-dicarboxylato-vanadate(V)
- Anti-inflammatory effect and isolation of phenylethanoid and acylated flavone glycosides from Panzeria alaschanica
- Synthesis and some reactions of functionalized 11,12-dihydro-5H-dibenzo[b,g]azonines
- Synthesis of some new mixed azines, Schiff and Mannich bases of pharmaceutical interest related to isatin
- Taraxastane-type triterpene saponins isolated from Pittosporum angustifolium Lodd.
- Synthesis and UV/Vis analysis of amino acid-derived bisurea-type receptors involving anion complexation
- Organoboranes and tetraorganoborates studied by 11B and 13C NMR spectroscopy and DFT calculations
- The stannides RE3Au6Sn5 (RE = La, Ce, Pr, Nd, Sm) – synthesis, structure, magnetic properties and 119Sn Mössbauer spectroscopy
- Synthesis and characterization of PbBaGeO4